Abstract: Vasohibins (VASH1 and VASH2) are recently identified regulators of angiogenesis and cancer cell functions. They are secreted proteins without any classical secretion signal sequences, and are thought to be secreted instead via an unconventional protein secretion (UPS) pathway in a small vasohibin-binding protein (SVBP)-dependent manner. However, the precise mechanism of SVBP-dependent UPS is poorly understood. In this study, we identified a novel UPS regulatory system in which essential domain architecture (VASH-PS) of VASHs, comprising regions VASH1 , regulate the cytosolic punctate structure formation in the absence of SVBP. We also demonstrate that SVBP form a complex with VASH1 through the VASH1 274-282 (SIa), VASH1 139-144 (SIb), and VASH1 133-137 (SIc), leading to the dispersion in the cytosol and extracellular release of VASH1. The amino acid sequences of VASH-SIa and VASH-PS, containing SIb and SIc, are highly conserved among VASH family members in vertebrates, suggesting that SVBPdependent UPS may be common within the VASH family. This novel UPS regulatory system may open up new avenues for understanding fundamental protein secretion in vertebrates.
Introduction
Vasohibin-1 (VASH1) and vasohibin-2 (VASH2) are members of the vasohibin family, a novel family of angiogenic regulators. [1] [2] [3] Spatiotemporal analyses of these genes in mice indicate that VASH1 and VASH2 have distinct expression patterns and opposing functions; VASH1 is mainly released from endothelial cells to terminate angiogenesis, while VASH2 is mainly expressed in mononuclear cells to promote angiogenesis. 4 In addition, VASH2 was found to be secreted from several types of cancer cells, including ovarian adenocarcinoma, 3 gastric cancer, 5 hepatocellular carcinoma, 6 endometrial cancer, 7 colon cancer, 8 breast cancer, 9 and pancreatic ductal adenocarcinoma, 10 where this protein acts to enhance tumor growth by promoting angiogenesis. No known functional motifs have been identified in either the VASH1 or VASH2 amino acid sequences, but order/disorder orientation analysis suggests that the N-and C-terminal disordered regions have distinct functions in both VASH1 and VASH2. 11 Most newly synthesized secretory proteins are secreted through the conventional endoplasmic reticulum (ER)-Golgi secretory pathway, in which proteins with a signal peptide are first recognized by a signal recognition particle and allowed to enter the ER, from where they are translocated to the Golgi apparatus using vesicles covered with coat protein complex II; they are then modified and processed in the Golgi, sorted into secretory vesicles, and finally released into the extracellular space. 12, 13 However, the VASHs contain no classical secretion signal sequences and are hypothesized to be released via nonconventional protein extracellular transport systems, the so-called UPS pathways, into the extracellular space. 1 So far, two types of UPS have been discovered: Interleukin (IL)21b, 14, 15 IL-33, 16 Acb1, [17] [18] [19] tissue transglutaminase, 20 galectin-3, 21 macrophage migration inhibitory factor, 22 and insulin-degrading enzyme 23 are all secreted through vesicle intermediates such as autophagosome-like vesicles, recycling endothomes, secretory lysosomes, multivesicular bodies, and exosomes, or via microvesicle shedding, 13, 24 whereas proteins such as the fibroblast growth factors (FGFs) are secreted via non-vesicular translocation across the plasma membrane. 13, 25 In the case of the VASHs, small vasohibin-binding protein (SVBP), a coiled-coil protein composed of 66 amino acids, 26 may be involved in the extracellular release of the VASHs, because overexpression or knockdown of SVBP has been shown to enhance or reduce VASH1 secretion, respectively. 26 However, the secretion mechanism of the VASHs via SVBP-dependent UPS is poorly understood. Here, we suggest a regulatory system of chaperone-dependent UPS by which SVBP promotes the extracellular release of the VASHs. Notably, we demonstrate that VASHs have a unique domain architecture containing critical sequences for distinct functions: PS formation, dispersion in the cytosol, and extracellular release. SVBP regulates these functions through sequence-specific interaction with the VASHs and translocates these proteins from the cytosol into the extracellular space on cellular demand.
Results

Analysis of subcellular localization and extracellular release of VASH1 by tracking system
Fluorescence and bioluminescence are highly sensitive tools for the spatial and quantitative analyses of intracellular and extracellular proteins. To analyze the subcellular localization and extracellular secretion of VASH1, superfolder green fluorescent protein (sfGFP) 27 or Renilla luciferase 8.6-535 (RLuc) 28 was fused to the C-terminal end of VASH1, constructing VASH1-sfGFP or VASH1-RLuc, respectively 29 [ Fig.   1 (A)]. SVBP was also fluorescently visualized by fusing it with a red fluorescent protein, mRuby2 30 [SVBPmRuby2; Fig. 1(A) ]. After transient transfection of VASH1-sfGFP cDNA into HeLa cells, VASH1 was found to show cytoplasmic PS formation [ Fig. 1(B) ], which did not fully overlap with any organelles examined, such as ER, mitochondria, or lysosome [ Fig. 1(C) ]. However, when VASH1 was coexpressed with SVBP or SVBP-mRuby2, these PS were completely absent and VASH1 was dispersed throughout the cytosol [ Fig.  1(B) ]. In our previous report, SVBP was shown to stabilize VASH1 by increasing its solubility and inhibiting ubiquitination in the cytosol, eventually enhancing VASH1 extracellular release. 26 Thus, we evaluated the level of VASH1 protein in both the culture medium and the cell lysate by measuring bioluminescence after coexpression of VASH1-RLuc and SVBP. In the presence of SVBP, VASH-1 fused to RLuc at the C-terminal end (VASH1-RLuc) significantly increase RLuc activity in the medium while VASH-1 fused to RLuc at the N-terminal end [RLuc-VASH1; Fig . These results demonstrate that N-terminal structure of VASH1 is important for SVBP-dependent dispersion in the cytosol and extracellular release and that the fusion of reporter proteins to the C-terminus successfully track the intracellular behavior of VASH1, revealing that VASH1 intrinsically shows PS formation in cells and that SVBP inhibits this PS formation and enhances extracellular release of VASH1.
Determination of the domain necessary for PS formation in VASHs
We hypothesized that VASH1 has domain architecture that facilitates the PS formation, and that SVBP can inhibit this PS formation by specific protein-protein interactions with VASH1, thereby enhancing the extracellular release of VASH1. To verify this hypothesis, we first identified the domain necessary for formation of PS within the VASH1 sequence (VASH1-PS). The cDNAs of various VASH1 deletion mutants, D1 (1-344), D2 (1-300), D3 the D4, D5, D6, D7, and D8 mutant proteins formed no visible PS in the cells, indicating that the region comprising amino acid residues 91-180 contains VASH1-PS. Human VASH2 (355 amino acid residues), a member of vasohibin family, has 52.5% amino acid sequence homology with human VASH1 (365 amino acid residues), 11 suggesting that a corresponding domain to VASH1-PS similarly facilitates the PS formation of VASH2 in the cytosol. Sequence alignment using ClustalW 31 
Analysis of domain architecture of VASH1-PS
To further analyze VASH1-PS, we designed the next set of deletion mutants based on the secondary 3(B) ], indicating that these regions are not required for PS formation. These results confirmed that the amino acid sequence 91-180 is necessary and sufficient for VASH1-PS, in which several essential domains for PS formation are connected via nonessential spacer sequence.
To understand the mechanism underlying PS formation of VASH1, we carried out in silico predictions of the surfaces of VASHs-PS with 10 ns molecular dynamic (MD) simulations. The 5.0-10.0 ns trajectories of VASH1-PS revealed that the coil and a-helix 2 are likely to form a positively charged anterior surface and that the a-helixes 1 and 3 compose hydrophobic posterior surface [ Fig. 3(C) ], suggesting that these deviations of surface potential in VASH1-PS contribute to PS formation.
Identification of motifs in VASH1 necessary for the SVBP-dependent cytosolic dispersion and extracellular release
To identify the amino acid sequences in VASH1 necessary for its SVBP-dependent dispersion in the cytosol, the mutant containing intact VASH1-PS and thus showing PS formation in the cytosol (D1, D2, D3, D9, D10, D15, D16, and D17 in Figs. 2 and 3) were coexpressed with SVBP in HeLa cells and their intracellular localization was observed [ Fig. 4(A) ]. Although D2 was distributed throughout the cell, D3 showed PS formation regardless of coexpression with SVBP, indicating the involvement of the 271-300 sequence in the SVBP-dependent dispersion in the cytosol. To further narrow down the sequence required for SVBPdependent dispersion of VASH1, D18 (274-282A), an alanine-substitution mutant in the 274-282 sequence (SIa), was constructed [ Fig. 4(B) ] and coexpressed with SVBP in HeLa cells. In this case, the SVBPdependent cytosolic dispersion was not observed, revealing that SIa is essential for this event [ Fig.  4(C) ]. In addition, among the alanine-substitution mutants (D15, D16, and D17) in PS domain, D15 and D17 showed SVBP-dependent cytosolic dispersion, while D16 did not, indicating that the 139-144 sequence (SIb) is also crucial for SVBP-dependent dispersion in the cytosol [ Fig. 4(A) ]. These results suggest that D15 and D17 may interact with SVBP but In the surface structures of VASH1-PS, the coil, a1, b1, a2, and a3 domains are highlighted in gray, magenta, orange, blue, and green, respectively. In the potential interacting surfaces, the positively charged and negatively charged regions are indicated in blue and red, respectively. D16 and D18 may not. To investigate the interaction between these mutants and SVBP, immunoprecipitation analysis was applied for these mutants and revealed that wild type VASH1 and D17 formed a complex with SVBP but neither D15, D16, nor D18 could [ Fig. 4(D) ]. These results indicate that in addition to SIa and SIb, sequence 133-137 (SIc) in PS domain is essential for the VASH1-SVBP complex formation and suggest that SIa and SIb are enough and necessary for interaction with SVBP to inhibit PS formation but not enough to make a tight complex formation.
To determine the causal relationships among cytosolic dispersion, the tight complex formation with SVBP, and extracellular release of VASH1, mutant proteins were fused to RLuc and expressed with SVBP in HeLa cells, followed by the measurement of the luciferase activities [ Fig. 4(E) ]. After 48 h incubation, we found that the extracellular release of the mutants that lacked either SIa or SIb (D3, D4, D5, D6, D7, D8, D9, D10, D11, D12, D13, D14, D16, and D18) was not enhanced by SVBP [ Fig. 4(E) ]. In contrast, the mutants having intact SIa and SIb (D1, D2, and D17) were increased in SVBP-dependent release from the cells, except for the D15 mutant [ Fig. 4(E) ], which lacks SIc [ Fig. 4(B) ]. SIc was required for the tight complex formation with SVBP as shown by fail of complex formation between SVBP and D15 mutant harboring alanine-substitution in SIc [ Fig. 4(D) ], suggesting the importance of the strong binding between VASH1 and SVBP for extracellular release. The D1, D2, and D17 mutants, which all contain SIa, SIb, and SIc, successfully exhibited SVBP-dependent extracellular release as indicated by the significantly high luciferase activity in their culture media.
Conservation of VASH-PS and SIa amino acid sequences among VASH family
Human VASH1-PS is highly conserved across the vertebrates except for reptiles (100% for chimpanzee, 100% for bovine, 97% for rat, 98% for mouse, 96% for chicken, 81% for zebrafish, and 80% for Xenopus). Notably, SIb and SIc are highly conserved and tryptophan residue within SIa is perfectly matched among these species (Fig. 5) . These results support the hypothesis that all three motifs, SIa, SIb, and SIc, play important roles in SVBP-dependent UPS of VASHs.
Discussion
In this study, we successfully demonstrated a novel UPS regulatory system, SVBP-dependent extracellular release of VASH1, by identifying the contributing small-domain architectures, SIa (274-EWKHSVLDV-282), SIb (139-QFFEIK-144) and SIc (133-QYNHT-137): SIa, SIb, and SIc are necessary for a physical association with SVBP and the extracellular release of VASH1 (Fig. 4) . These motifs are highly conserved among VASH family members in the vertebrates (Fig. 5) , strongly suggesting that VASH proteins uses the same secretion mechanism as VASH1, while opposite function between VASH1 and VASH2 may be due to their disordered regions in the N-and C-termini.
To understand the VASHs' UPS, we constructed a series of VASH1 mutants and analyzed their behavior by fluorescence-and luciferase-reporter tracking systems (summarized in Table I ). The results suggest that VASH's UPS are controlled by SVBP through two distinct regulations. The first regulation is PS formation. In the absence of SVBP, VASHs form PS in the cytosol and thus their secretion is suppressed. Mutants' analysis revealed that Figs. 1-3 ) and VASH2-PS (sequence 80-169 of VASH2, Fig. 2 ) are crucial elements for the PS formation of these proteins in the cytosol. Because predictive structures of VASH1-PS based on the MD simulations revealed that the positively charged anterior is exposed on the surface [ Fig. 3(C) ] and because amphipathic peptides such as MPG and Pep-1, which are composed of positively charged and hydrophobic amino acids, have been known to associate rapidly with oligonucleotides and polypeptides through noncovalent electrostatic or hydrophobic interactions and to form stable complexes with them, 33 we have proposed a possible mechanism showing PS formation of VASHs in the cytosol: VASH1-PS may directly form complexes with oligonucleotides and polypeptides in the cytosol via its positively charged anterior surface. In addition, positively charged proteins can bind to negatively charged anionic lipids such as phosphatidylglycerol, phosphatidylserine, phosphatidic acid, and phosphatidylinositol, 34 suggesting that VASH1-PS may bind anionic lipids within some membrane structures to form PS in the cytosol. What VASH-PS is bound to in the cytosol is under investigation but membranes of the ER, mitochondria and lysosome may not become candidates because the PS did not fully overlap with them [ Fig. 1(C) ]. The second regulation is tight complex formation with SVBP. Coexpression of SVBP with VASH1 completely inhibits VASH1 PS formation and facilitates its secretion [ Figs. 1(D) and 4 ]. VASH1 mutants lacking either SIa or SIb motif (D16 and D18), which are not able to form a complex with SVBP, exhibited PS even when SVBP was coexpressed (Fig. 4) , indicating that the complex formation through SIa and SIb motifs is essential for SVBP-dependent dispersion in the cytosol and extracellular release. The requirement of complex formation with SVBP for VASH-extracellular release is exhibited by the VASH1-PS mutants with an intact SIc (D4, D11, and D12), which were able to disperse in the cytosol regardless of SVBP expression (Figs. 2 and 3 ), but failed to be released into the extracellular space (Fig. 4) and a substitution mutation in SIc (D15), which dispersed in the cytosol in the presence of SVBP but failed to be released due to inability to form a tight complex with SVBP (Fig. 4) .
VASH1-PS (sequence 91-180 of VASH1,
From these results, we propose a SVBP-dependent UPS pathway of the VASHs (Fig. 6) . VASHs intrinsically form PS probably through binding to unknown targets in the cytosol via positively charged sequences in their PS domain [ Fig. 6-a] , and upon secretory stimulation SVBP enhances the UPS of VASHs via two chaperone functions in the cytosol: SVBP inhibits the PS formation of VASHs by forming a tight complex via SI motifs, leading to dispersion of VASHs in the cytosol [ Fig. 6-b, 6-c] , and then interact with the plasma membrane [ Fig. 6-d] , resulting in their release into the extracellular space via an unknown mechanism [ Fig.  6 -e]. This process may be involved in as yet undefined pathways, which include vesicle intermediates and direct export.
We previously reported that the full-length VASH1 protein (44 kDa) is post-translationally processed, resulting in at least three smaller forms (42, 36 , and 27 kDa) 35 and also that the 42 kDa (sequence 30-365) protein was mainly detected in 
᭺, intact; 1, positive response; 2, negative response; /, not done.
the cytosol, whereas the 36 kDa (sequence 77-365) and 27 kDa (sequence 77-318) proteins were extensively secreted in the presence of SVBP. 26 All secretable truncated forms contain VASH1-PS and VASH1-SIa, supporting the critical importance of this domain architecture for their secretion. Although the extracellular release of the truncated 42 and 36 kDa protein are easily evaluated using cells expressing VASH1-sfGFP and -RLuc, we are not able to detect the truncated 27 kDa protein, which lacks C-terminal region of VASH1. However, D2 (1-300) shows SVBPdependent extracellular release, suggesting that truncated C-terminal region (319-365) of 27 kDa protein has few functions on the extracellular release. IL-1b, one of the major inflammatory factors known to be secreted through UPS, is secreted via secretory vesicle intermediates. 15 However, in our study, no vesicle-like structures were observed when VASH1-sfGFP was coexpressed with SVBP in the cells (Fig. 1) , indicating that the UPS of VASHs may not be mediated by vesicular translocation across the plasma membrane, similarly to the FGFs. 13 During the UPS of FGF2, its attachment to the plasma membrane through the binding of PtdIns(4,5)P 2 was proposed as the first essential step, followed by the insertion of FGF2 oligomers into the membrane-spanning hydrophilic pore and externalization by the binding of membrane-proximal heparin sulfate proteoglycans on the extracellular surface of the plasma membrane. 13, 25, 36 VASHs use a novel UPS mechanism by binding to SVBP that has a coiledcoil structure similar to the membrane-anchoring proteins such as the golgin proteins, which function in the conventional protein secretion system, 37, 38 suggesting that SVBP may recruit VASHs into the plasma membrane. The VASH-SVBP complexes possibly then penetrate the plasma membrane through their positively charged molecular surface, as cationic proteins and peptides have been similarly observed to penetrate mammalian cells. 33, 39 Further study should reveal the precise molecular mechanism of SVBP-mediated UPS of the VASHs.
Vertebrates have highly specialized blood cells such as erythrocytes, thrombocytes and leukocytes, 40 and control vascular homeostasis with a sophisticated vascular network. VASH1-PS is highly conserved among the vertebrates including humans (Fig. 5) , suggesting that SVBP-dependent UPS may be a fundamental cellular mechanism for controlling vascular homeostasis. 
Materials and Methods
Human cell line and culture conditions
The human cervical cancer cell line HeLa was purchased from the American Type Culture Collection (Manassas, VA) and maintained at 378C in 5% FBS Dulbecco's Modified Eagle's Medium (Thermo Fisher Scientific, Waltham, MA) supplemented with 100 units/mL penicillin and 100 lg/mL streptomycin (Nacalai Tesque, Kyoto, Japan).
Plasmid construction for recombinant VASH1, VASH2, SVBP, and mutant proteins
The cDNAs encoding the wild-type and D1-D18 mutant VASH1 proteins each fused with sfGFP or RLuc were inserted into the EcoRV site of the pcDNA3.1 plasmid (Thermo Fisher Scientific). The cDNAs encoding full-length VASH2 or domain for the PS formation of VASH2 (residues 80-169) fused with sfGFP and for SVBP fused with mRuby2 were also inserted into the EcoRV site of separate pcDNA3.1 plasmids.
Intracellular localization of VASH1, VASH2, SVBP, and mutant proteins
The plasmids for the expression of wild-type and mutant VASH1 or VASH2 fused with sfGFP (0.125 lg each) were co-transfected with 0.125 lg of p33FLAG-SVBP, the plasmid for the expression of SVBP-mRuby2 fusion protein, or empty pcDNA3. 
Immunoprecipitation
The plasmids for the expression of VASH1-RLuc, D15-RLuc, D16-RLuc, D17-RLuc, D18-RLuc, or empty pcDNA3.1 vector (2.5 lg each) were cotransfected with 2.5 lg of p33FLAG-SVBP or empty pcDNA3.1 vector, into HeLa cells in 10-cm dishes (1.0 3 10 6 cells/ dish in 10 mL medium) and the cells were incubated for 48 h at 378C. Cells were lysed in the buffer consisting of 20 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2 mM EDTA, and 1% Triton X-100. Cell extracts were placed on ice for 15 min and then centrifuged at 12,000g for 10 min to collect the supernatant. The cell lysate was incubated with mouse monoclonal anti-Flag antibody (catalogue no. F3165, Sigma-Aldrich, St. Louis, MO) for 1 h at 48C and then protein G sepharose beads (GE Healthcare, Little Chalfont, United Kingdom) for another 1 h at 48C. The beads were washed three times with the lysis buffer and then immunoprecipitated proteins were eluted into Laemmli sample buffer. The protein samples were separated on 12.5% SDS-polyacrylamide gel and transferred to Hybond ECL membranes (GE Healthcare). VASH1-RLuc and SVBP-Flag were detected with rabbit polyclonal antiRenilla luciferase antibody (catalogue no. PM047, Medical and Biological Laboratories, Aichi, Japan) and mouse monoclonal anti-Flag antibody (SigmaAldrich), respectively. Appropriate horseradish peroxidase-conjugated secondary antibodies were obtained from CST.
MD simulations
The initial coordinates for VASH1 91-180 were generated from the arylamine N-acetyltransferase 3 (NAT3) structure (PDB ID code: 4DMO), which was previously proposed to be a protein of vasohibin-like family. 42 The secondary structures of VASH1 91-180 were deployed to the corresponding positions of NAT3 . The system was optimized via energy minimization, and equilibrated with backbone restraints. Then 10.0 ns production run was performed for trajectory analysis using the Amber 14 program on TSUBAME (Global Scientific Information and Computing Center, Tokyo Institute of Technology). The parameters for the MD simulations were force field 5 Amber ff14SB, solvent model 5 GB/SA, time step 5 2 fs with the SHAKE algorithm, non-bonded cutoff 5 999.9 Å , and temperature 5 300 K using the Berendsen rescaling method.
Statistical analyses
Statistical analyses were carried out with the Student's t-test. Values of P < 0.005 were considered statistically significant.
